Candice McCoy

626 total citations
27 papers, 501 citations indexed

About

Candice McCoy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Candice McCoy has authored 27 papers receiving a total of 501 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 18 papers in Pulmonary and Respiratory Medicine and 7 papers in Molecular Biology. Recurrent topics in Candice McCoy's work include Prostate Cancer Treatment and Research (16 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Candice McCoy is often cited by papers focused on Prostate Cancer Treatment and Research (16 papers), Cancer Immunotherapy and Biomarkers (15 papers) and Radiopharmaceutical Chemistry and Applications (6 papers). Candice McCoy collaborates with scholars based in United States, United Kingdom and Germany. Candice McCoy's co-authors include Marilyn M. Cornwell, Dirk E. Smith, Cindy L. O’Bryant, S. Gail Eckhardt, Lia Gore, Astrid Schott, Mace L. Rothenberg, Alan B. Sandler, Catherine Scholz and Neal D. Shore and has published in prestigious journals such as Journal of Clinical Oncology, Molecular and Cellular Biology and Clinical Cancer Research.

In The Last Decade

Candice McCoy

27 papers receiving 482 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Candice McCoy United States 11 286 233 171 106 52 27 501
Caterina Aversa Italy 12 210 0.7× 285 1.2× 222 1.3× 62 0.6× 108 2.1× 32 553
Kishore Shakalya United States 4 204 0.7× 120 0.5× 85 0.5× 116 1.1× 24 0.5× 6 423
Constance M. Cultraro United States 14 381 1.3× 166 0.7× 109 0.6× 49 0.5× 65 1.3× 30 510
Karijn Floor Netherlands 10 400 1.4× 244 1.0× 179 1.0× 59 0.6× 100 1.9× 12 588
Daphne L. Farrington United States 12 293 1.0× 155 0.7× 71 0.4× 111 1.0× 53 1.0× 19 471
Roy Elias United States 11 165 0.6× 191 0.8× 141 0.8× 56 0.5× 62 1.2× 40 411
Deepa Prabhavalkar United States 2 228 0.8× 295 1.3× 183 1.1× 38 0.4× 29 0.6× 2 477
Cathy E. Nolan United States 6 384 1.3× 206 0.9× 61 0.4× 68 0.6× 51 1.0× 8 585
Patricia Bukczynska Australia 13 360 1.3× 170 0.7× 119 0.7× 125 1.2× 126 2.4× 23 545
Leticia Tetteh United States 6 197 0.7× 306 1.3× 112 0.7× 149 1.4× 23 0.4× 11 456

Countries citing papers authored by Candice McCoy

Since Specialization
Citations

This map shows the geographic impact of Candice McCoy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Candice McCoy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Candice McCoy more than expected).

Fields of papers citing papers by Candice McCoy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Candice McCoy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Candice McCoy. The network helps show where Candice McCoy may publish in the future.

Co-authorship network of co-authors of Candice McCoy

This figure shows the co-authorship network connecting the top 25 collaborators of Candice McCoy. A scholar is included among the top collaborators of Candice McCoy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Candice McCoy. Candice McCoy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Olson, N. Eric, Seamus P. Ragan, David J. Reiss, et al.. (2023). Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel. Molecular Cancer Therapeutics. 22(3). 406–418. 8 indexed citations
2.
Small, Eric J., Raymond S. Lance, Thomas A. Gardner, et al.. (2015). A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 21(17). 3862–3869. 61 indexed citations
3.
4.
5.
Tutrone, Ronald, Chiledum Ahaghotu, Andrew J. Armstrong, et al.. (2015). Characteristics of African Americans (AAs) treated with sipuleucel-T (sip-T): Comparison of clinical trial and real-world experience.. Journal of Clinical Oncology. 33(7_suppl). 272–272. 2 indexed citations
6.
Higano, Celestia S., Oliver Sartor, Nicholas J. Vogelzang, et al.. (2015). Administration of sipuleucel-T (sip-T) infusions (infs) outside of the clinical trial setting: Data from the PROCEED registry.. Journal of Clinical Oncology. 33(15_suppl). e16027–e16027. 1 indexed citations
7.
Bajorin, Dean F., Leonard G. Gomella, Padmanee Sharma, et al.. (2014). Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence.. Journal of Clinical Oncology. 32(15_suppl). 4541–4541. 5 indexed citations
8.
Vogelzang, Nicholas J., Jeffrey Vacirca, Philip W. Kantoff, et al.. (2014). Effect of prior abiraterone (ABI) or enzalutamide (ENZ) on sipuleucel-T (sip-T) manufacture in PROCEED patients (pts).. Journal of Clinical Oncology. 32(4_suppl). 185–185. 1 indexed citations
9.
Antonarakis, Emmanuel S., Adam S. Kibel, George W. Adams, et al.. (2014). 980 A randomized phase 2 study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically-recurrent prostate cancer (BRPC): Immune results with a focus on humoral responses. European Urology Supplements. 13(1). e980–e980b. 3 indexed citations
10.
11.
Small, Eric J., Raymond Lance, Thomas A. Gardner, et al.. (2013). A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 31(6_suppl). 114–114. 16 indexed citations
12.
Antonarakis, Emmanuel S., Adam S. Kibel, Robert Claude Tyler, et al.. (2013). Randomized phase II trial evaluating the optimal sequencing of sipuleucel-T and androgen-deprivation therapy (ADT) in patients (pts) with biochemically recurrent prostate cancer (BRPC).. Journal of Clinical Oncology. 31(6_suppl). 34–34. 9 indexed citations
13.
Antonarakis, Emmanuel S., Adam S. Kibel, George W. Adams, et al.. (2013). A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results.. Journal of Clinical Oncology. 31(15_suppl). 5016–5016. 14 indexed citations
14.
Shore, Neal D., C.A. Mantz, Daniel E. Dosoretz, et al.. (2013). Building on Sipuleucel-T for Immunologic Treatment of Castration-Resistant Prostate Cancer. Cancer Control. 20(1). 7–16. 17 indexed citations
15.
Small, Eric J., Raymond S. Lance, Charles H. Redfern, et al.. (2013). A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 31(15_suppl). 5047–5047. 22 indexed citations
16.
Scott, Edwina N., Anne Thomas, L Rhoda Molife, et al.. (2009). A phase I dose escalation study of the pharmacokinetics and tolerability of ZK 304709, an oral multi-targeted growth inhibitor (MTGI™), in patients with advanced solid tumours. Cancer Chemotherapy and Pharmacology. 64(2). 425–429. 32 indexed citations
17.
18.
Graham, Janet, Karl Wagner, Ruth Plummer, et al.. (2006). Phase I dose-escalation study of novel oral multi-target tumor growth inhibitor (MTGI) ZK 304709 administered daily for 7 days of a 21-day cycle to patients with advanced solid tumors. Journal of Clinical Oncology. 24(18_suppl). 2073–2073. 4 indexed citations
19.
Gore, Lia, Scott N. Holden, M. Basche, et al.. (2004). Updated results from a phase I trial of the histone deacetylase (HDAC) inhibitor MS-275 in patients with refractory solid tumors. Journal of Clinical Oncology. 22(14_suppl). 3026–3026. 17 indexed citations
20.
McCoy, Candice, et al.. (1999). The Wilms' tumor suppressor, WT1, inhibits 12-O-tetradecanoylphorbol-13-acetate activation of the multidrug resistance-1 promoter.. PubMed. 10(6). 377–86. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Caterina Aversa Breakdown of academic impact, for papers by Kishore Shakalya Breakdown of academic impact, for papers by Constance M. Cultraro Breakdown of academic impact, for papers by Karijn Floor Breakdown of academic impact, for papers by Daphne L. Farrington Breakdown of academic impact, for papers by Roy Elias Breakdown of academic impact, for papers by Deepa Prabhavalkar Breakdown of academic impact, for papers by Cathy E. Nolan Breakdown of academic impact, for papers by Patricia Bukczynska Breakdown of academic impact, for papers by Leticia Tetteh
Rankless by CCL
2026